Big Tech stocks created, and have so far dominated, the trillion-dollar club in the US. For the first time, there’s a race brewing for an outsider to join their ranks. Bre Bradham and Angel Adegbesan report bloomberg.com/news/articles/… via Bloomberg Markets

Who will be the next trillion-dollar powerhouse in the US? Hint: It's not Tech! Reported with Bre Bradham edits by Cristin Flanagan bloomberg.com/news/articles/… via Bloomberg Markets

Watch out, tech giants. Berkshire Hathaway and Eli Lilly are also making runs toward trillion-dollar valuations Bre Bradham & Angel Adegbesan (LLY BRK) bloomberg.com/news/articles/…

After years of misery investors who piled into LSD, ecstasy and other psychedelic-tied drug stocks are betting that 2024 is their breakout moment bloomberg.com/news/articles/… @angeladegbesan reports on $MNMD $ATAI $GHRS $CMPS

After years of losses, investors who piled into LSD, Ecstasy and other psychedelic drug stocks are betting that 2024 is their breakout moment bloomberg.com/news/articles/… via Bloomberg Markets

Friday scoop: Ares, Blue Owl lead a $4.8 billion private credit deal for Novo Holdings buyout of @CatalentPharma — one of the biggest of all time. With Ellen Schneider and John Sage: bloomberg.com/news/articles/…

Scoop: Adobe's been keeping a little secret about its AI. Its Firefly model was branded as more ethical than rivals like Midjourney. But it was actually trained on images from them. With Rachel Metz bloomberg.com/news/articles/…

going to tell my kids this was Jack Harlow

🏇Some pre-Derby Day reading: Churchill Downs, the company that owns the event and the track where it takes place, is showing that its business is about more than just horse racing bloomberg.com/news/articles/… my latest via Bloomberg:

Hope for a weight-loss drug that’s better than Ozempic and Wegovy has sent Viking Therapeutics' shares skyrocketing, but the drug developer needs a partner — or a buyer - to get to the next level. bloomberg.com/news/articles/… via Bloomberg

A flurry of deals at the start of the year sparked optimism for a biotech stock resurgence but a swing in sentiment at the direction of interest rates has left the sector hanging in limbo bloomberg.com/news/articles/… via Angel Adegbesan

For my latest Bloomberg story, I dug into 450 pages of rider complaints sent to NJ Transit to illustrate a system plagued by years of underinvestment and a tricky relationship with its landlord, Amtrak. “NJ Transit is ruining my life," one rider wrote. bloomberg.com/features/2025-…

NEWS: The list of ~20 countries that the US is engaging in initial trade talks with includes major exporters that the US has publicly mentioned (Japan, South Korea)— but also small economies (Fiji, Lesotho, Mauritius) w/ Josh Wingrove Jennifer A. Dlouhy bloomberg.com/news/articles/…

When CFRA’s Paige Meyer slapped a “sell” rating on UnitedHealth in February, she was the lone analyst out of 30 tracked by Bloomberg with a negative view of the company bloomberg.com/news/articles/…